Effects of metformin in women with polycystic ovary syndrome treated with gonadotrophins for in vitro fertilisation and intracytoplasmic sperm injection cycles: a systematic review and meta‐analysis of randomised controlled trials
- 30 November 2012
- journal article
- review article
- Published by Wiley in BJOG: An International Journal of Obstetrics & Gynaecology
- Vol. 120 (3) , 267-276
Abstract
Background: Metformin is widely used for treating women with polycystic ovary syndrome (PCOS), and many patients with PCOS who are infertile receive gonadotrophins while being treated with metformin.Objectives: To assess the effects of metformin administration in infertile patients with PCOS who receive gonadotrophins for in vitro fertilisation (IVF) and intracytoplasmic sperm injection (ICSI) cycles.Search strategy: We searched international scientific databases, websites for the registration of trials, and bibliographies of retrieved articles, books, and review articles up to August 2012.Selection criteria: Randomised controlled trials (RCTs).Data collection and analysis: Authors independently reviewed and extracted the data.Main results: Ten RCTs (with a total of 845 women with PCOS) were included in the final analysis. Metformin administration in IVF/ICSI cycles had no effect on the rates of pregnancy (OR 1.20, 95% CI 0.90–1.61) and live birth (OR 1.69, 95% CI 0.85–3.34). No effect of metformin dose, metformin pretreatment duration, and stopping time of metformin administration was observed on these reproductive end points. Metformin administration reduced the risk of ovarian hyperstimulation syndrome (OHSS; OR 0.27, 95% CI 0.16–0.46) and of miscarriage (OR 0.50, 95% CI 0.30–0.83), while increased that of implantation (OR 1.42, 95% CI 1.24–2.75).Author's conclusions: In infertile patients with PCOS treated with gonadotrophins for IVF/ICSI cycles, metformin exerts no clinical effect on rates of pregnancy or live birth, but it reduces the risk of OHSS, and improves the rates of miscarriage and implantation. Further RCTs are needed to assess the reproductive effect of metformin in young well‐selected patients with PCOS and specific phenotypes and features.Keywords
This publication has 31 references indexed in Scilit:
- Metformin reduces risk of ovarian hyperstimulation syndrome in patients with polycystic ovary syndrome during gonadotropin-stimulated in vitro fertilization cycles: a randomized, controlled trialFertility and Sterility, 2011
- Pregnancy in women with polycystic ovary syndrome: the effect of different phenotypes and features on obstetric and neonatal outcomesFertility and Sterility, 2010
- Serum and follicular anti-Mullerian hormone levels in women with polycystic ovary syndrome (PCOS) under metforminJournal of Ovarian Research, 2010
- Management strategies for ovulation induction in women with polycystic ovary syndrome and known clomifene citrate resistanceCurrent Opinion in Obstetrics and Gynecology, 2009
- Does metformin affect ovarian morphology in patients with polycystic ovary syndrome? A retrospective cross-sectional preliminary analysisJournal of Ovarian Research, 2009
- Metformin in the treatment of clomiphene citrate-resistant women with polycystic ovary syndrome undergoingin vitrofertilisation treatment: A randomised controlled trialJournal of Obstetrics and Gynaecology, 2009
- Metformin-Induced Stimulation of Adenosine 5′ Monophosphate-Activated Protein Kinase (PRKA) Impairs Progesterone Secretion in Rat Granulosa Cells1Biology of Reproduction, 2006
- The effect of metformin on ovarian stimulation and in vitro fertilization in insulin-resistant women with polycystic ovary syndrome: an open-label randomized cross-over trialGynecological Endocrinology, 2003
- Decreases in Ovarian Cytochrome P450c17α Activity and Serum Free Testosterone after Reduction of Insulin Secretion in Polycystic Ovary SyndromeNew England Journal of Medicine, 1996
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986